UNDERSTAND THE TOTAL MARKET SIZE AND TREATMENT OPPORTUNITIES FOR BIOMARKERS
The development of biomarker-driven therapies continues to be a major trend in oncology. As biomarkers are often clinically relevant in more than one indication, the concept of sizing eligible patient populations is evolving. With DRG Biomarker Epidemiology data and insights, the entire biomarker-defined population can be sized in minutes.
EGFR
RAS
BRCA
ALK
Breast Cancer
x
x
x
Renal Cell Carinoma
x
Ovarian Cancer
x
Prostate Cancer
x
Pancreatic Cancer
x
x
Colorectal Cancer
x
x
x
Non-Small-Cell Lung Cancer
x
x
x
Head and Neck Cancer
x
Thyroid Carcinoma
x
Small-Cell Lung Cancer
x
Rare Tumors
x
x
Source: Clarivate
EPIDEMIOLOGY IS THE FOUNDATION OF MARKET FORECASTING AT ALL PHASES OF PRODUCT DEVELOPMENT AND STRATEGY
You need biomarker epidemiology data you can trust in order to:
Complete biomarker-driven market sizing assessments based on patient population sizes and patient flows.
Build the foundation of a market forecast for strategic planning for biomarker-targeting for new and existing assets.
Understand how the patient populations for certain biomarkers will evolve over time.
Answer any question you may have about specific subpopulations, biomarkers, and the impact of new studies.
DRG BIOMARKER EPIDEMIOLOGY REPORTS
DRG Epidemiology has created a robust repository of the prevalence of biomarker and mutation-defined treatment-eligible cancer populations. With DRG’s Biomarker Epidemiology you can now save months of time and resources researching each individual tumor in which a biomarker may be significant. Quickly access data on biomarker patient population sizes, based on diverse eligibility criteria and treatment settings.
In addition to an extensive literature review and modeling, we leverage our in-house estimates of cancer incidence for solid and hematological malignancies. All our estimates are rigorously researched and transparently reported.
ADDITIONAL CAPABILITIES
Patient Flow Diagrams
Customizable populations and data visualization dashboards
Testing rates and companion diagnostic information
Real world data augmentation
Patient journey and demographic characteristics
Real world analysis of associated comorbidities and treatments
Diagnosed Incidence of RAS-Mutated Cancers per 100,000 People of All Ages in 2021 and 2031
Analysis of the Diagnosed Incidence of RAS-Mutated Cancers in 2021 by Site
Patient-Flow Diagram for RAS-Mutated Cancers in 2021
Epidemiology Data
Methods
Diagnosed RAS-Mutated Incident Cases
Diagnosed RAS-Mutated Colorectal Cancer Incident Cases
Diagnosed RAS-Mutated NSCLC Incident Cases
Diagnosed KRAS-Mutated Pancreatic Cancer Incident Cases
Diagnosed RAS-Mutated First-Line Drug-Treatable Population
Diagnosed RAS-Mutated First-Line Colorectal Cancer Drug-Treatable Population
Diagnosed RAS-Mutated First-Line NSCLC Drug-Treatable Population
Diagnosed KRAS G12C-Mutated First-Line NSCLC Drug-Treatable Population
Diagnosed RAS-Mutated First-Line Pancreatic Cancer Drug-Treatable Population
Reference Materials
Literature Review
Studies Included in the Analysis of the Prevalence of RAS-Mutated NSCLC, Colorectal Cancer, and Pancreatic Cancer
Studies Excluded from the Analysis of the Prevalence of RAS-Mutated NSCLC, Colorectal, and Pancreatic Cancers
Risk / Protective Factors
Bibliography
Abbreviations
Glossary
Mudasir Khan, M.P.H.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.
